New Identity Affirmation Project Helps Trans and Non-Binary People in the Name Change Process OutBuro lgbtq professional entreprenuer networking online community transgender queer nonbinary

New “Identity Affirmation Project” Helps Trans and Non-Binary People in the Name Change Process

BOSTON, Nov. 2, 2021 /PRNewswire/ — A new student-led project has officially launched under the Center for Law and Social Responsibility at New England Law | Boston: The Identity Affirmation Project.

Learn more at www.nesl.edu/IAP.

Founded by law students Katharine Nakaue (she/they) and Greg Newman-Martinez (he/him), both in the evening program at New England Law, the Identity Affirmation Project aims to assist transgender, non-binary, and gender-nonconforming people in the process of legally changing their name or gender marker in Massachusetts, including probate court filings.

When a person identifies by a name or gender other than what was assigned at birth, they may seek to legally change their name or gender marker so official documents match their identity. The project’s mission is to guide people through often overwhelming legal steps at no cost.

After months of research, building community connections, and securing final approval from the Law Center’s Director, Professor David Siegel (he/him), the Identity Affirmation Project (IAP) is officially accepting participant inquiry forms from individuals who wish to start the legal name change process. For now, participants must be U.S. citizens, Massachusetts residents, and at least 18 years of age.

Co-founder Greg Newman-Martinez says they hope to expand services as the project grows. “We are so excited to be able to fill this need and provide some peace of mind for trans,  non-binary, and gender-nonconforming adults in Massachusetts. During the pilot phase, we successfully assisted several clients and also discovered that we would be able to take on more clients than originally anticipated. My hope, in addition to seeing this project continue to grow, is that similar services will be available across the country, and ultimately that these processes will become less burdensome.”

The probate filing process is often the most difficult to navigate. IAP participants receive assistance filing in probate court, and with name or gender marker changes on the following documentation:

  • Social Security Card
  • MA Driver’s License
  • U.S. Passport
  • MA Birth Certificate
  • Other documents as needed

Fees associated with these documents may apply. Services through the Identity Affirmation Project are provided at no cost to the participant and volunteers can assist with seeking a waiver for court fees. Student volunteers guide participants through the probate and documentation processes with oversight from the project’s faculty advisor, Director of the Center for Law and Social Responsibility at New England Law, Professor David Siegel.

Siegel explained the importance of such work for the students as well as the individuals receiving assistance. “Fostering student-initiated, student-driven, and student-led projects like this is exactly why we created the Center for Law and Social Responsibility. Students who recognize critical legal needs and develop ways to meet them become lawyers who have impact.”

For more details, contact information, and an inquiry form for interested participants, visit www.nesl.edu/IAP.

ABOUT NEW ENGLAND LAW | BOSTON
New England Law | Boston was founded in 1908 as Portia Law School, the first and only law school established exclusively for the education of women. Today, New England Law offers its co-ed student body flexible, convenient programs that combine rigorous academics, dynamic community, and early access to practical experience, as well as a diverse, global alumni network spanning 29 countries, 50 states, and 99 practice areas. For more information, visit www.nesl.edu.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/new-identity-affirmation-project-helps-trans-and-non-binary-people-in-the-name-change-process-301414123.html

SOURCE New England Law | Boston

rt

Moderna Reaffirms Commitment to Job Creation in Massachusetts

Company recently announced expansion of the Moderna Technology Center in Norwood, MA

Company has nearly doubled the size of its workforce since March 31, 2020 and continues to grow

Company commits to hiring at least 155 new Massachusetts-based employees for high-tech manufacturing positions in 2021 and retaining through 2025

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today reaffirmed its commitment to job creation in Massachusetts. Over the last year, Moderna nearly doubled the size of its workforce, from approximately 830 employees as of March 31, 2020 to approximately 1,500 employees as of March 31, 2021. In the last year, Moderna created more than 650 new jobs at its manufacturing facility in Norwood, Massachusetts. The Company continues to expand in Norwood and Cambridge.

KO LOGO

On June 15, Moderna was awarded a tax incentive from the Massachusetts Life Sciences Center (MLSC) based on its commitment to hire 155 new full-time equivalent employees in 2021 and retaining that headcount through 2025. The MLSC Tax Incentive Program awards companies engaged in life science research and development, commercialization and manufacturing with the goal of creating new, long-term jobs in the state of Massachusetts.

“I would like to thank the Massachusetts Life Sciences Center and the Baker-Polito Administration for this recognition of our commitment to creating new, high-tech employment opportunities in Massachusetts. We have been based in the Commonwealth since our founding more than 10 years ago and we opened our manufacturing facility in Norwood in 2018. This facility has been integral to our long-term strategy and helped anchor our manufacturing capacity as we worked relentlessly to combat the COVID-19 pandemic,” said Stéphane Bancel, Chief Executive Officer of Moderna. “Massachusetts continues to be the global leader in the biotech industry and having our manufacturing facility in Norwood has enabled close collaboration with our research and development teams in Cambridge. It’s also allowed us to work with state and local partners and to leverage the incredible innovation and diverse talent from the Massachusetts life sciences and technology sectors. We are proud to create new biotech and manufacturing jobs in Massachusetts as we work to develop new mRNA medicines.”

Moderna recently announced an expansion of the Moderna Technology Center in Norwood, including more than doubling of space to transform the facility from a production and lab space to an industrial technology center. This expansion includes increasing the Company’s production and lab space from approximately 300,000 square feet to approximately 650,000 square feet through renovation of existing space and entering into a long-term lease of a 240,000 square foot building located on the same campus for expansion of its commercial and clinical activities. The expansion also includes an increase in Moderna’s technical development capacity and preclinical production capability.

The Company’s expansion in Norwood will support a 50% increase in production of the Moderna COVID-19 Vaccine from its manufacturing site, which is expected to ramp up in late 2021 and early 2022. On April 29, Moderna announced an investment at its owned and partnered manufacturing facilities that it expects will increase 2022 global capacity to up to 3 billion doses of its COVID-19 vaccine, depending upon the mix between the authorized Moderna COVID-19 Vaccine at the 100 μg dose level and potentially lower doses of the Company’s variant booster candidates and pediatric vaccines, if authorized.

Moderna opened its Norwood manufacturing site in July 2018. Digital technology is integrated throughout the site—the entire research, development and production process incorporates advanced robotics, machine learning, artificial intelligence and creative design. Designed to Current Good Manufacturing Practices (cGMP), this expansion gives the Company the capacity and flexibility to support the manufacture of the Company’s commercial COVID-19 vaccine and the other programs in Moderna’s clinical development pipeline. In addition, the site was built with attention to environmental sustainability and to qualify for LEED certification.

About Moderna

In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna’s capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.

Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Today, 24 development programs are underway across these therapeutic areas, with 14 programs having entered the clinic. Moderna has been named a top biopharmaceutical employer by Science for the past six years. To learn more, visit www.modernatx.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: the Company’s development of a vaccine to protect against the SARS-CoV-2 virus (mRNA-1273, also referred to as the Moderna COVID-19 Vaccine); anticipated production of the Moderna COVID-19 Vaccine in 2021 and 2022; and the Company’s hiring and employment plans within the state of Massachusetts. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include those other risks and uncertainties described under the heading “Risk Factors” in Moderna’s most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof.

Contacts

Media:
Colleen Hussey

Director, Corporate Communications

617-335-1374

Colleen.Hussey@modernatx.com

Investors:
Lavina Talukdar

Senior Vice President & Head of Investor Relations

617-209-5834

Lavina.Talukdar@modernatx.com